Publications by authors named "Natalia Bartoszewicz"
Background: A personalised approach to the treatment of acute myeloid leukemia (AML) in children and adolescents, as well as the development of supportive therapies, has significantly improved survival. Despite this, some patients still die before starting treatment or in an early phase of therapy before achieving remission. The study analysed the frequency, clinical features and risk factors for early deaths (ED) and treatment related deaths (TRD) of children and adolescents with AML.
View Article and Find Full Text PDFBackground: The reports of studies that compare the survival of adolescents and young adults with younger children with acute myeloid leukemia (AML) are contradictory.
Patients And Methods: We retrospectively analyzed 220 AML patients aged 0-18 years treated in pediatric oncologic centers in Poland from 2015 to 2022. The evaluated group included 31 infants (below 1 year), 91 younger children (1-9.
Characteristics and Outcome of FLT3-ITD-Positive Pediatric Acute Myeloid Leukemia-Experience of Polish Pediatric Leukemia and Lymphoma Study Group from 2005 to 2022.
Cancers (Basel)
September 2023
Article Synopsis
- The FLT3 gene mutation occurs in 10-15% of pediatric acute myeloid leukemia (AML) cases and is linked to poorer outcomes in patients.
- A study analyzed data from 2005 to 2022, revealing that FLT3-ITD-positive patients had significantly lower survival rates compared to those without the mutation.
- Results indicated that treatment advancements, like FLT3 inhibitors and stem cell transplants, improved survival rates, while additional genetic mutations (WT1 and NPM1) impacted prognosis significantly.
Therapy results in pediatric Hodgkin lymphoma reflect remarkable progress in pediatric oncology. In the last decade, relevant development of new therapeutic options for children with refractory or relapsed disease has been made. In this study, we retrospectively analyzed therapy results and risk factors in children treated in a single oncology center according to five therapeutic protocols.
View Article and Find Full Text PDFAcute P./myeloid leukemia post cytotoxic therapy (AML-pCT) is rare complication of cancer treatment in childhood. The objective of the study was to identify clinical characteristics and provide an analysis of the outcomes in pediatric AML-pCT.
View Article and Find Full Text PDFAdvances in the First Line Treatment of Pediatric Acute Myeloid Leukemia in the Polish Pediatric Leukemia and Lymphoma Study Group from 1983 to 2019.
Cancers (Basel)
September 2021
Article Synopsis
- From 1983 to 2019, Poland implemented standardized protocols for treating pediatric acute myeloid leukemia (AML), analyzing treatment results from 899 children over various time periods.
- Survival rates improved significantly, with three-year overall survival increasing from 34% to 75% across the different therapeutic protocols, along with reductions in early deaths and deaths in remission.
- Advances in treatment strategies, focusing on genetic factors and supportive care, contributed to better outcomes, particularly for patients with challenging genetic profiles in the most recent treatment period.
Background: Oral mucositis (OM) is considered to be one of the worst and most debilitating complications of conditioning for hematopoietic cell transplantation (HCT). Prevention and treatment of this complication is one of the utmost priorities of supportive therapy during transplant procedure. The objective of this study was the analysis of the influence of palifermin, keratinocyte growth factor (KGF), on transplant outcomes in patients undergoing allo-HCT.
View Article and Find Full Text PDFEpidemiology, Outcome and Risk Factors Analysis of Viral Infections in Children and Adolescents Undergoing Hematopoietic Cell Transplantation: Antiviral Drugs Do Not Prevent Epstein-Barr Virus Reactivation.
Infect Drug Resist
December 2019
Article Synopsis
- The study analyzed viral infections in children and adolescents who underwent hematopoietic cell transplantation (HCT), involving 971 procedures over six years.
- A high incidence of viral infections (57.9% in allo-HCT vs. 4.8% in auto-HCT) was recorded, mainly from cytomegalovirus (CMV), BK virus (BKV), and Epstein-Barr virus (EBV), with most infections occurring within the first four months post-transplant.
- Risk factors for these infections included allo-HCT, certain types of leukemia, and graft versus host disease (GVHD), with antiviral treatments often ineffective at preventing EBV reactivation.
Article Synopsis
- The study focused on how immune recovery affects patients after receiving allogeneic hematopoietic stem cell transplants (allo-HSCT), particularly in children.
- Researchers analyzed data from 65 children to identify factors that influence the speed of immune system recovery.
- Key findings indicated that factors like the source of stem cells (peripheral blood), presence of certain viral infections (CMV and EBV), and younger recipient age significantly affect the recovery of various lymphocyte subpopulations.